MABC539

Sigma-Aldrich

Anti-SFRP2 Antibody, clone 80.8.6, azide free

clone 80.8.6, from mouse

Synonyme(s):
Secreted frizzled-related protein 2, FRP-2, sFRP-2, Secreted apoptosis-related protein 1, SARP-1
eCl@ss:
32160702
NACRES:
NA.41

Niveau de qualité

100

Source biologique

mouse

antibody product type

primary antibodies

Clone

80.8.6, monoclonal

species reactivity

human

Application(s)

immunohistochemistry: suitable
inhibition assay: suitable

Isotype

IgG2aκ

N° d'accession NCBI

N° d'accession UniProt

Expédié(e)(s) dans

wet ice

Gene Information

human ... SFRP2(6423)

Description générale

Secreted frizzled-related proteins (SFRPs) may play a critical role in carcinogenesis by inhibiting the Wnt/beta-catenin signaling pathway. Secreted frizzled-related protein 2 (SFRP2) may be useful to further investigate mammary tumorigenesis as its expression increases with tumor progression in canine mammary gland tumors. SFRP2 in mouse embryos has been found to cause severe shortening of the thoracic region. Studies have shown that this protein is the essential stem cell paracrine factor that is thought to regulate myocardial survival and repair damage in the aftermath of an ischemic injury.

Immunogène

Epitope: NTR domain
Linear peptide corresponding to the NTR domain of human SFRP2.

Application

Inhibition Assay Analysis: Anti-SFRP2, clone 80.8.6 inhibits tube formation and cell migration in vitro on SVR angiosarcoma cells, inhibits angiosarcoma and breast cancer growth in vivo, and increases nuclear NFATc3 levels.
Anti-SFRP2 Antibody, clone 80.8.6, azide free is an antibody against SFRP2 for use in IHC & inhibition.

Qualité

Evaluated by Immunohistochemistry in human prostate and human breast cancer tissue.

Imunnohistochemistry Analysis: A 1:500 dilution of this antibody detected SFRP2 in human prostate and human breast cancer tissue.

Description de la cible

33 kDa calculated

Forme physique

Format: Purified

Autres remarques

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

WGK Allemagne

WGK 1

Flash Point(F)

Not applicable

Point d'éclair C

Not applicable

Certificat d'analyse
Certificat d'origine
A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth.
Fontenot, Emily, et al.
Molecular Cancer Therapeutics, 12, 685-695 (2013)
Amanpreet Kaur et al.
Nature, 532(7598), 250-254 (2016-04-05)
Cancer is a disease of ageing. Clinically, aged cancer patients tend to have a poorer prognosis than young. This may be due to accumulated cellular damage, decreases in adaptive immunity, and chronic inflammation. However, the effects of the aged microenvironment...
Mitchell E Fane et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(21), 5709-5719 (2020-10-25)
Angiogenesis is thought to be critical for tumor metastasis. However, inhibiting angiogenesis using antibodies such as bevacizumab (Avastin), has had little impact on melanoma patient survival. We have demonstrated that both angiogenesis and metastasis are increased in older individuals, and...
Y Sun et al.
Oncogene, 35(33), 4321-4334 (2016-01-12)
Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME...

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique

Réseaux sociaux

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Recherche. Développement. Production

Nous sommes un des tout premiers fournisseurs du secteur mondial des Sciences de la vie proposant des solutions et des services pour la recherche, le développement et la production en biotechnologies, et le développement et la production de produits thérapeutiques pharmaceutiques.

© 2021 Merck KGaA, Darmstadt, Allemagne et/ou ses sociétés affiliées. Tous droits réservés.

La reproduction d'une quelconque partie du contenu de ce site est strictement interdite sans autorisation.